Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -22.72%3.82B | 27.33%1.92B | -59.78%670M | 4.50%1.35B | -123.65%-114M | -19.24%4.94B | -6.23%1.5B | 17.82%1.67B | -19.32%1.29B | -67.91%482M |
Net income from continuing operations | -35.55%1.37B | -425.95%-603M | -23.29%573M | 29.23%924M | -0.21%473M | -45.46%2.12B | -47.59%185M | 30.59%747M | -56.51%715M | -64.09%474M |
Operating gains losses | -435.00%-67M | 416.13%160M | 433.33%20M | -2,383.33%-274M | 258.82%27M | 500.00%20M | 55.00%31M | -123.08%-6M | 154.55%12M | 41.38%-17M |
Depreciation and amortization | -0.78%1.52B | 2.37%389M | 3.81%381M | -1.02%387M | -7.83%365M | 21.07%1.53B | 13.77%380M | 15.41%367M | 28.62%391M | 27.33%396M |
Deferred tax | -1,116.28%-437M | -7,060.00%-358M | -182.76%-24M | -453.85%-46M | -250.00%-9M | -88.35%43M | -101.75%-5M | 93.33%29M | 118.84%13M | -95.62%6M |
Other non cash items | 36.72%242M | 296.77%244M | -47.73%138M | 53.25%236M | -221.37%-376M | 152.21%177M | 50.79%-124M | 29.41%264M | 741.67%154M | 56.18%-117M |
Change In working capital | -88.85%30M | 52.65%1.09B | -414.56%-497M | 234.04%63M | -12.72%-629M | -40.22%269M | -0.14%716M | -30.40%158M | 90.04%-47M | -2,436.36%-558M |
-Change in receivables | 15.45%127M | 37.76%540M | 312.22%191M | 29.89%113M | -156.99%-717M | -89.05%110M | -54.99%392M | -109.35%-90M | 143.50%87M | 55.64%-279M |
-Change in inventory | 38.89%25M | 114.02%458M | -164.05%-98M | -656.67%-227M | 66.14%-108M | 119.78%18M | -58.04%214M | 182.26%153M | 89.93%-30M | -172.65%-319M |
-Change in payables and accrued expense | -186.52%-122M | -13.64%95M | -721.05%-590M | 270.19%177M | 390.00%196M | 130.39%141M | 116.57%110M | 117.27%95M | -500.00%-104M | -94.48%40M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -22.72%3.82B | 27.33%1.92B | -59.78%670M | 4.50%1.35B | -123.65%-114M | -19.24%4.94B | -6.23%1.5B | 17.82%1.67B | -19.32%1.29B | -67.91%482M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -4.28%-1.85B | 9.74%-547M | -12.59%-483M | 15.63%-313M | -37.47%-510M | 10.12%-1.78B | -11.40%-606M | -7.52%-429M | 35.81%-371M | 18.64%-371M |
Capital expenditure reported | -20.12%-1.84B | -4.13%-504M | 6.60%-368M | -60.80%-484M | -37.22%-483M | 18.99%-1.53B | ---484M | ---394M | ---301M | ---352M |
Net business purchase and sale | 235.29%138M | 76.29%-23M | -800.00%-27M | ---- | ---- | -1,027.27%-102M | ---97M | ---3M | ---- | ---- |
Net investment purchase and sale | -44.58%46M | 33.33%28M | ---- | ---- | ---- | -26.55%83M | --21M | ---- | ---- | ---- |
Net other investing changes | 12.78%-198M | -4.35%-48M | -12.77%-106M | 75.00%-17M | -42.11%-27M | -7.58%-227M | 43.90%-46M | -44.62%-94M | -47.83%-68M | -5.56%-19M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -4.28%-1.85B | 9.74%-547M | -12.59%-483M | 15.63%-313M | -37.47%-510M | 10.12%-1.78B | -11.40%-606M | -7.52%-429M | 35.81%-371M | 18.64%-371M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 2.82%-1.9B | -27.90%-518M | 42.65%-484M | -114.73%-481M | 13.63%-412M | 42.76%-1.95B | 15.27%-405M | -57.17%-844M | 86.66%-224M | 33.10%-477M |
Net issuance payments of debt | 74.40%-32M | ---1M | --0 | --0 | ---31M | -3,025.00%-125M | --0 | -4,622.22%-425M | 9.49%300M | --0 |
Net common stock issuance | 7.58%-195M | ---78M | -2.44%-42M | 25.00%-75M | --0 | 49.76%-211M | --0 | 74.05%-41M | -122.22%-100M | 67.74%-70M |
Cash dividends paid | -6.83%-1.72B | -7.64%-437M | -7.37%-437M | -7.35%-438M | -4.88%-408M | 50.40%-1.61B | -4.91%-406M | -3.04%-407M | 80.51%-408M | -4.85%-389M |
Net other financing activities | 1,400.00%52M | -300.00%-2M | -117.24%-5M | 300.00%32M | 250.00%27M | -101.52%-4M | -88.89%1M | 16.00%29M | -108.65%-16M | -140.91%-18M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 2.82%-1.9B | -27.90%-518M | 42.65%-484M | -114.73%-481M | 13.63%-412M | 42.76%-1.95B | 15.27%-405M | -57.17%-844M | 86.66%-224M | 33.10%-477M |
Net cash flow | ||||||||||
Beginning cash position | 57.93%3.41B | -7.35%2.64B | 14.84%2.86B | 29.21%2.33B | 57.93%3.41B | 45.97%2.16B | 91.39%2.84B | 133.96%2.49B | 0.56%1.8B | 45.97%2.16B |
Current changes in cash | -94.16%71M | 72.41%850M | -175.57%-297M | -20.29%554M | -183.06%-1.04B | 65.31%1.22B | -15.29%493M | -17.78%393M | 205.62%695M | -209.91%-366M |
Effect of exchange rate changes | -358.82%-88M | -242.65%-97M | 258.14%68M | -320.00%-21M | -371.43%-38M | 160.71%34M | -22.73%68M | 25.86%-43M | 92.86%-5M | 187.50%14M |
End cash Position | -0.50%3.39B | -0.50%3.39B | -7.35%2.64B | 14.84%2.86B | 29.21%2.33B | 57.93%3.41B | 57.93%3.41B | 91.39%2.84B | 133.96%2.49B | 0.56%1.8B |
Free cash flow | -41.95%1.98B | 38.33%1.41B | -76.26%302M | -12.64%864M | -559.23%-597M | -19.34%3.41B | -9.81%1.02B | 30.46%1.27B | -7.31%989M | -87.69%130M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |